05:32 AM EDT, 09/04/2024 (MT Newswires) -- Mainz Biomed ( MYNZ ) said Wednesday that it expanded its collaboration with Liquid Biosciences to include PancAlert, Mainz Biomed's ( MYNZ ) detection test for pancreatic cancer.

The company said the expanded collaboration will allow it to leverage Liquid Biosciences' proprietary artificial intelligence analysis technology platform EMERGE to "expand and optimize" novel biomarkers selection for PancAlert.

Mainz Biomed ( MYNZ ) said the collaboration's first phase evaluated biomarkers from its research program and based on the results, the partners determined that a PancAlert diagnostic test could be combined with Mainz Biomed's ( MYNZ ) colorectal cancer screening product in the future.

The partners plan to continue with the second phase of the collaboration, which covers the evaluation of microbiome biomarkers that were analyzed in collaboration with Microba Life Sciences in 2023, according to the statement. This analysis is expected to be completed in Q4, said Mainz Biomed ( MYNZ ).